ProCE Banner Activity

Phase I/II Trial of CD3 x CD20 Bispecific Antibody Epcoritamab (GEN3013) in R/R B-Cell NHL

Slideset Download
Conference Coverage

Epcoritamab was associated with rapid, deep responses and low-grade CRS in heavily pretreated patients with R/R NHL.

Released: June 05, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono